AR084388A1 - Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen - Google Patents
Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR084388A1 AR084388A1 ARP110101775A ARP110101775A AR084388A1 AR 084388 A1 AR084388 A1 AR 084388A1 AR P110101775 A ARP110101775 A AR P110101775A AR P110101775 A ARP110101775 A AR P110101775A AR 084388 A1 AR084388 A1 AR 084388A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- heteroaryl
- group
- heterocycle
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), donde: A’ se selecciona del grupo formado por un enlace simple, -(CR2)n-C(O)-(CR2)p-, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)(CR2)p-, -(CR2)n-S(O)k-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p-, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p-, y -(CR2)n-N(RN)-C(O)-O-(CR2)p- y un grupo heteroarilo seleccionado del grupo de formulas (2) donde: X1 es CH2, NH, O ó S; Y1, Y2 y Z1 son, cada una, independientemente CH o N; X2 es NH, O ó S; V es -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b o (CH2)a-O-(CH2)b, donde a y b son independientemente 0, 1, 2 ó 3 con la condición de que a y b no sean ambas 0, el resto de formula (3) opcionalmente incluye 1 ó 2 nitrógenos como heteroátomos en el residuo fenilo, los carbonos del grupo heteroarilo están, cada uno, independiente y opcionalmente sustituidos con un sustituyente seleccionado del grupo que consiste en halógeno, -OH, -CN, -NO2, halógeno, alquilo C1-12, heteroalquilo C1-12 heteroalquilo, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino, los nitrógenos, si están presentes, del grupo heteroarilo son, cada una, independiente y opcionalmente sustituidos con un sustituyente seleccionado del grupo formado por -OH, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato y sulfonamida; a y b son independientemente 1, 2 ó 3; c y d son independientemente 1 ó 2; n y p son independientemente 0, 1, 2 ó 3; k es 0, 1 ó 2; cada R se selecciona independientemente del grupo formado por hidrógeno, halógeno, -OH, -CN, -NO2, halógeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino; cada RN se selecciona independientemente del grupo formado por hidrógeno, -OH, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato y sulfonamida y donde B puede estar unido a cualquiera de los lados de A’ de manera que, cuando el resto de la formula (4), es el ejemplo A’, W-B-A’ puede ser un compuesto de formula (5) ó (6); B y B’ son, cada una, independientemente un anillo de 4 a 8 miembros que es un arilo, heteroarilo, cicloalquilo o heterociclo donde cada heteroátomo, si está presente, es, independientemente N, O ó S y donde al menos uno de B o B’ es aromático; cada Ra se selecciona independientemente del grupo formado por -OH, -CN, -NO2, halógeno, alquilo C1-12, alquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino; y si B o B’ no es aromático, también puede sustituirse con uno o más oxo; cada r es, independientemente 0, 1, 2 ó 3; W se selecciona independientemente entre el grupo de formulas (7), donde: X1 es CH2, NH, O ó S; Y1, Y2 y Z1 son, cada una, independientemente CH o N; X2 es NH, O ó S; V es -CH2-CH2-, -CH=CH-, -N=CH, (CH2)a-N(RN)-(CH2)b- o -(CH2)a-O-(CH2)b, donde a y b son independientemente 0, 1, 2 ó 3 con la condición de que a y b no sean ambas 0, el resto de formula (3) opcionalmente incluye 1 ó 2 nitrógenos como heteroátomos en el residuo fenilo; W se sustituye opcionalmente con uno o más sustituyentes seleccionados del grupo formado por -OH, -CN, -NO2, halógeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino, W y el anillo B’ pueden conectarse a través de un átomo de carbono o un átomo de nitrógeno en B’; y Cy es un grupo cicloalquilo, heterociclo, arilo o heteroarilo monocíclico, bicíclico o tricíclico de 5 a 12 miembros donde hasta tres heteroátomos son independientemente N, S u O y que está opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo formado por -OH, -CN, -NO2, halógeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino; cada Rc, Rd, Re y Rf se selecciona independientemente del grupo formado por: hidrógeno, alquilo C1-8, heteroalquilo C1-8, aralquilo y un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclo, heteroarilo o arilo, donde, cada heteroátomo, si está presente, es independientemente N, O ó S, cada uno de Rc, Rd, Re y Rf puede estar opcionalmente sustituido por alquilo C1-8, heteroalquilo C1-8, aralquilo, o un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclo, heteroarilo o arilo y donde cada heteroátomo, si está presente, es independientemente N, O ó S, Re y Rd están opcionalmente ligados para formar un heterociclo de 4 a 8 miembros que está opcionalmente fusionado a otro anillo heterociclo o heteroarilo de 3 a 5 miembros, y Re y Rf están opcionalmente ligados para formar un heterociclo de 4 a 8 miembros que está opcionalmente fusionado a otro anillo heterociclo o heteroarilo de 3 a 5 miembros; Y e Y’ son, cada uno, independientemente carbono o nitrógeno; y Z y Z’ se seleccionan independientemente del grupo formado por hidrógeno, alquilo C1-8 alquilo, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, 1 - 3 aminoácidos, -[U-(CR42)t-NR5-C(R42)t]u-U-(CR42)t-NR7-(CR42)t-R8, -U-(CR42)t-R8, y -[U-(CR42)t-NR5-(CR42)t]u-U-(CR42)t-O-(CR42)t-R8, donde, U se selecciona del grupo formado por -C(O)-, -C(S)- y -S(O)2-; cada R4, R5 y R7 se selecciona independientemente del grupo formado por hidrógeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo; R8 se selecciona del grupo formado por hidrógeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81 y -S(O)2-N-R812, donde cada R81 se elige independientemente del grupo formado por hidrógeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo, opcionalmente, R7 y R8 juntos forman un anillo de 4 - 7 miembros; cada t es independientemente 0, 1, 2, 3 ó 4, y u es 0, 1 ó 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34778810P | 2010-05-24 | 2010-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084388A1 true AR084388A1 (es) | 2013-05-15 |
Family
ID=45004316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101775A AR084388A1 (es) | 2010-05-24 | 2011-05-24 | Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen |
Country Status (6)
Country | Link |
---|---|
US (2) | US8877707B2 (es) |
EP (1) | EP2575866A4 (es) |
AR (1) | AR084388A1 (es) |
CA (1) | CA2800509A1 (es) |
TW (1) | TW201202220A (es) |
WO (1) | WO2011149856A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2767887A1 (en) | 2009-07-16 | 2011-01-20 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
PE20130395A1 (es) | 2010-06-24 | 2013-04-10 | Gilead Sciences Inc | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral |
WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2730572B1 (en) | 2011-07-09 | 2015-09-16 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
US8946238B2 (en) | 2011-12-22 | 2015-02-03 | Gilead Sciences, Inc. | Pyrazolo[1,5-A]pyrimidines as antiviral agents |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2013221613A1 (en) * | 2012-02-13 | 2014-09-04 | Presidio Pharmaceuticals, Inc. | Solid forms comprising inhibitors of HCV NS5A, compositions thereof, and uses therewith |
KR102181318B1 (ko) * | 2012-04-17 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 화합물 및 방법 |
TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
CN103848818B (zh) | 2012-11-29 | 2017-03-15 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用 |
TWI585082B (zh) | 2012-11-29 | 2017-06-01 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途 |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ |
WO2015110048A1 (en) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
US10626094B2 (en) * | 2014-10-14 | 2020-04-21 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
ITUB20152784A1 (it) * | 2015-08-03 | 2017-02-03 | Chemelectiva S R L | Processo per la sintesi di ravidasvir |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
MA43169B1 (fr) | 2015-11-06 | 2022-05-31 | Incyte Corp | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma |
CN113717154A (zh) | 2015-12-10 | 2021-11-30 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
CN105753765A (zh) * | 2016-04-15 | 2016-07-13 | 浙江美诺华药物化学有限公司 | 一种奇拉西酮中间体的制备方法 |
CN107445948B (zh) * | 2016-05-30 | 2021-02-09 | 苏州朗科生物技术股份有限公司 | 一种新型药物中间体化合物及其制备方法和用途 |
TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
USD856715S1 (en) | 2016-06-29 | 2019-08-20 | Bruce Robins | Combined display tablet dock and table |
CN107663196A (zh) * | 2016-07-27 | 2018-02-06 | 广东东阳光药业有限公司 | 制备化合物的方法 |
WO2018204176A1 (en) | 2017-05-01 | 2018-11-08 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof |
WO2018226622A1 (en) * | 2017-06-05 | 2018-12-13 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
BR112019027717A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
EP3645121A4 (en) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | HUNTINGTON'S DISEASE TREATMENT METHODS |
JOP20200086A1 (ar) | 2017-10-18 | 2020-04-30 | Incyte Corp | مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما |
KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
CA3103976A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
PE20211815A1 (es) | 2018-09-05 | 2021-09-14 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
SK286662B6 (sk) | 1996-04-23 | 2009-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty močoviny, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie ako inhibítorov aktivity IMPDH enzýmu |
CA2268391A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
WO1998040381A1 (en) | 1997-03-14 | 1998-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
US6010848A (en) | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
ES2234144T3 (es) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | Analogos de peptidos inhibidores de la hepatitis c. |
ES2244204T3 (es) | 1998-07-27 | 2005-12-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Derivados de dicetoacidos como inhibidores de polimerasas. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
CN1325309A (zh) | 1998-08-21 | 2001-12-05 | 维洛药品公司 | 用于治疗或预防病毒感染和相关疾病的化合物、组合物和方法 |
CA2343522A1 (en) | 1998-09-04 | 2000-03-16 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
AU751457B2 (en) | 1998-09-25 | 2002-08-15 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
EP1964561A1 (en) | 1999-03-19 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
WO2001085172A1 (en) | 2000-05-10 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
WO2002100846A1 (en) | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
CN100509797C (zh) | 2001-06-11 | 2009-07-08 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
DE60221875T2 (de) | 2001-11-02 | 2007-12-20 | Glaxo Group Ltd., Greenford | 4-(6-gliedrige)-heteroaryl-acyl-pyrrolidinderivate als hcv-inhibitoren |
JP2005511573A (ja) | 2001-11-02 | 2005-04-28 | グラクソ グループ リミテッド | Hcv阻害剤としての4−(5−員)−ヘテロアリールアシルピロリジン誘導体 |
EP1440068A1 (en) | 2001-11-02 | 2004-07-28 | Glaxo Group Limited | Acyl dihydro pyrrole derivatives as hcv inhibitors |
US7608590B2 (en) | 2004-01-30 | 2009-10-27 | Medivir Ab | HCV NS-3 serine protease inhibitors |
US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
EP2049481A2 (en) | 2006-08-09 | 2009-04-22 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists for opioid receptors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
KR20130130875A (ko) | 2009-02-27 | 2013-12-02 | 이난타 파마슈티칼스, 인코포레이티드 | C형 간염 바이러스 억제제 |
EP2475254A4 (en) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
MX2012010252A (es) * | 2010-03-04 | 2013-02-01 | Enanta Pharm Inc | Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv). |
-
2011
- 2011-05-23 EP EP11787204.4A patent/EP2575866A4/en not_active Withdrawn
- 2011-05-23 WO PCT/US2011/037618 patent/WO2011149856A1/en active Application Filing
- 2011-05-23 CA CA2800509A patent/CA2800509A1/en not_active Abandoned
- 2011-05-23 US US13/699,707 patent/US8877707B2/en not_active Expired - Fee Related
- 2011-05-24 AR ARP110101775A patent/AR084388A1/es unknown
- 2011-05-24 TW TW100118192A patent/TW201202220A/zh unknown
-
2014
- 2014-11-03 US US14/531,764 patent/US20150057218A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2011149856A1 (en) | 2011-12-01 |
US20150057218A1 (en) | 2015-02-26 |
US20130203656A1 (en) | 2013-08-08 |
US8877707B2 (en) | 2014-11-04 |
EP2575866A1 (en) | 2013-04-10 |
CA2800509A1 (en) | 2011-12-01 |
TW201202220A (en) | 2012-01-16 |
EP2575866A4 (en) | 2013-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084388A1 (es) | Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen | |
AR080263A1 (es) | Inhibidores ns5a de vhc | |
AR081831A1 (es) | Inhibidores de la proteina ns5a del virus de la hepatitis c (vhc) | |
AR074474A1 (es) | Inhibidores ns5a de vhc | |
AR076164A1 (es) | Inhibidores de anillos fusionados de hepatitis c | |
AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
AR084720A1 (es) | Inhibidores de anillos fusionados triciclicos de hepatitis c | |
AR071452A1 (es) | Inhibidores de hsp90 | |
AR068794A1 (es) | Compuestos antivirales | |
CO5611110A2 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos | |
AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
AR066458A1 (es) | Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas. | |
CO5550501A2 (es) | Derivados nucleosidos con accion sobre el virus de la hepatitis c, su procedimiento de sintesis y composiciones que los contienen | |
AR082888A1 (es) | Compuestos de piridina para la inhibicion de nampt | |
ES2546502T3 (es) | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas | |
AR075051A1 (es) | Compuestos antidiabeticos que contienen ftalazina | |
AR061840A1 (es) | Compuestos fosfinatos antivirales | |
CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
AR039554A1 (es) | Compuestos derivados de aminopirimidina y aminopiridina, su empleo, un metodo para su preparacion, composiciones que los comprenden, y compuestos intermediarios | |
AR049170A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
AR082887A1 (es) | Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt | |
AR076550A1 (es) | Inhibidores de la janus tirosina kinasa (jak) | |
AR058700A1 (es) | Compuestos heterociclicos como bloqueadores del canal de sodio epitelial | |
AR054838A1 (es) | Compuestos inhibidores del virus de la hepatitis c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |